Life Sciences Archive » December, 2011

Life Sciences - December, 2011

152 articles

• Doctors Seek High Court Reversal Of DNA Patentability
• Bristol-Myers Escapes Navy Encryption IP Suit
• FDA Warns Of New Baby Acetaminophen Dosage Risks
• Santarus Tries To Shoot Down Zydus' Generic Zegerid
• Canada, EU To Probe Novartis Diabetes Drug
• Hospira Investors Go After Board Over Inflated Stock Prices
• DNA Probe Patent Suit Belongs In California: Fed. Circ.
• HGS Execs Hid Lupus Drug's Suicide Link: Suit
• Sanofi, Sun Settlement Ends Plavix Patent Case
• Ripe For Comment: The CMS Sunshine Rule
• Black & Decker, Others Sued For Dump Site Cleanup Costs
• In Pursuit Of Financial Fraudsters
• J&J Targets 12M Bottles Of Motrin In Latest Recall
• Wal-Mart Pulls Enfamil Formula After Infant Death
• Novartis, Others Can't Stop Generic Tobramycin Suit
• SC AG Can't Skirt AstraZeneca Improper Penalty Claims
• Tris Pharma Kicks Cough Syrup Infringement Claims
• Genentech Sues Dr. Reddy's Over Generic Valcyte
• Kelley Drye Lands 2 Schiff Hardin IP Partners
• Immersion Beats $300M Suit Over Pumped-Up Stock Prices
• French Doctor Gets Time Served For Insider Trading
• House Asks DHS To Fork Over Docs On $433M SIGA Deal
• Judge Won't Nix $327M Verdict Over J&J's Risperdal
• Ranbaxy Settles With FDA, Sets Aside $500M For DOJ Probe
• Bard Picks Up Device Maker Lutonix For $325M
• France Calls For Removal Of 30,000 Breast Implants
• Merck Reaches $24M Deal To End Mass. Medicaid Suit
• Ex-NFL Player Fronted Heart Device Co. Stock Scam: SEC
• New VC Fund To Invest $75M In Early-Stage Health Cos.
• Pfizer, Sandoz Agree To End Caduet Patent Fight
• Judge Trims J&J Investor Suit Over Kids' Meds Recalls
• Smith & Nephew's $85M Win Axed In Suture Anchor IP Row
• SIGA Can't Scrap Smallpox Drug Profit-Share Ruling
• Rejecting Brand-Liability Theory Post-Mensing
• FDA Tightens Restrictions On Sanofi's Multaq
• FCA Recoveries Top $3B For 2nd Year In A Row
• Pfizer, Others To Shell Out $6M For Superfund Cleanup
• Pfizer Seeks To Stymie Sandoz, Accord's Generic Torisel
• HHS To Let States Set Benefit Benchmarks For Health Plans
• New FDA Rules To Up Women In Medical Device Studies
• Sens. Float Bill To Improve Watch Over Medical Devices
• KV Again Shakes Suit Over Metoprolol Recall
• Scrutinizing Reverse-Payment Settlements
• Shire Takes Aim At Mylan Again In New Intuniv Patent Suit
• Kimberly-Clark Sues Cardinal Over Sterilization Wrap IP
• J&J Unit Aims To Thwart Sandoz's Generic Doribax
• Teva Unit Targets Celgene Breast Cancer Drug In IP Suit
• Shearman Aids Fujifilm In $995M Buy Of Ultrasound Co.
• J&J Unit Hits Covidien With Surgical Tool Patent Suit
• Covidien To Separate $2B Pharmaceuticals Unit
• Cipro Pay-For-Delay Suit Heads To Calif. High Court
• Merck Sells NJ Office Building To PE Venture
• Cancer Institute Says Doctor Stole $1B In Research
• JPML Won't Merge 12 Actions Over Plavix Injuries
• Sealing The Deal: Skadden Splits Diabetes Drug Alliance
• Martek Can't Duck Baby Formula Ingredients Antitrust Suit
• Bayer's Off-Label Yaz Marketing Violated FCA: Watchdog
• Widening The Class Certification Circuit Split
• Biotech REIT Scores Boston Lab Complex For $308M
• Watson Pays $27M To Exit Drug Inflation MDL
• DOJ Sets Record-High $6B Fraud Recovery In 2011
• DOJ Seeks To Add $1M To Mass. $13M Cleanup Settlement
• Ironwood Lied To Patent Offices: $500M Suit
• FDA Blasts Medical Centers Over Deceptive Lap-Band Ads
• FDA Ducks Contempt Claim After Nixing OTC Contraceptives
• Warner Chilcott Takes Aim At Lupin's Generic Generess Fe
• Baxter Scoops Up Synovis For $325M
• 4th Exec Jailed For Illicit Human Testing Of Bone Cement
• Sidley Austin Welcomes Greenberg IP Pro To SF Office
• The No-Injury Warranty Claims Quandary
• Determining Patentability Of Personalized Medicine
• Merck Urges 3rd Circ. To OK Pay-For-Delay Settlements
• Medtronic Investors Win Cert. In Off-Label Marketing Case
• Medtronic Strikes $23.5M Deal In Doctor Kickbacks Dispute
• Gibson Dunn Lures New FDA Practice Leader From Sidley
• Impax's Generic Amrix Must Stay Banned: Cephalon, Mylan
• Symmetry Picks Up J&J Unit's Surgical Tool Line For $165M
• Pharmacies' Pfizer Merger Appeal Stays Out Of High Court
• Valeant Cedes Drugs To Win OK For $770M Skin Care Buys
• Fed. Circ. Nixes Injunction On Mylan's Generic Doryx
• Vaccine Purchasers Accuse Sanofi Of Stifling Competition
• SEC Targets Glaxo Unit Over Underpriced Stock Buybacks
• Teva Settles Suit Over Watson's Generic LoSeasonique
• Ex-Shionogi IT Employee Gets 3.5 Years For Hacking
• Valeant Ends Fight With Par Over Generic Antidepressant
• Hospira Misled Investors To Pump Up Stock Prices: Suit
• FTC, Boehringer Wrangle Over Generics Settlement Docs
• Australia To Step Up Regulation Of Homeopathics
• Merck Scores Patent Extension Win In EU High Court
• 6th Circ. Backs Ex-B. Braun Worker In Off-Label Drug Case
• Two Firsts In Post-Mensing Litigation
• Pfizer Settles Menopause Drug Suit After $73M Verdict
• How To Tell Auditors About A Fraud Investigation
• Bayer Should Stress Clot Risk On Yaz Label: FDA Panel
• Wal-Mart Launches FCPA Compliance Probe
• American Laser Heads To Ch. 11 To Ease Sale
• Calif. AG Seeks Medtronic Bone Graft Docs
• Pfizer Sues Alembic Over Lyrica ANDA
• Novartis, Celgene Hit Teva Again Over ADHD Drug Patents
• UK Pushes Full Exam For $7.8B Private Medical Industry
• LabCorp's $85M Orchid Deal Depends On Divestment: FTC
• Nutter Pulls In Former Pfizer Patent Pro
• Fed. Circ. Affirms Cephalon Win In Generic Fentora IP Suit
• Brand's Off-Label Promotion: Valuable Tool For Generics
• Covert Investigations And Ethical Considerations
• J&J, Coloplast, Others Face Cancer Treatment Patent Suit
• High Court Ponders Limits Of Patentability In Mayo Suit
• Drugmakers Sue Wockhardt Over Tricor ANDA
• House OKs Bill To Boost Congress' Power Over Regulations
• HealthpointCapital Takes On Surgical Tool Maker Blue Belt
• Lab-Focused REIT Nets $600M Loan To Restructure Debt
• Humana Picks Up Health Analytics Leader Anvita
• Bayer Battles Generic Yasmin Hopeful In Fed. Circ.
• Medline Seeks To Avoid Bill For Surgical Mesh Suits
• Plan B Birth Control Still Requires Prescription, HHS Says
• Lannett Cuts Deal With Celgene In Thalomid Antitrust Case
• Caraco V. Novo Nordisk — A Divided Supreme Court
• Conditions Of Participation And Payment As Qui Tam Defense
• Buying A Distressed Hospital Out Of Bankruptcy
• Pfizer Hit With $73M Verdict In Menopause Drug Suit
• Lupin Must Halt Sales Of Generic Diabetes Drug: Judge
• Express Scripts Exec Defends $29B Merger To Lawmakers
• FDA Eases Risk Mandates For GSK, Amgen Platelet Drugs
• FDA To Weigh Public Input On Biosimilars Program
• KV Pharma To Shell Out $17M In FCA Settlement
• Shire Patent Suit Dismissal Will Delay Generic: Alkem
• J&J Pays $2M To Exit Idaho AG's Drug Pricing Suit
• Software Co. SuccessFactors Buys Jobs2Web For $110M
• Targeting Health Care Execs Under Park Doctrine
• Bayer Covered Up Yasmin Blood Clot Risk: Ex-FDA Head
• GOP Sens. Urge FTC To Probe $29B Express Scripts Merger
• Class Attys Get $1.5M In Allstate Cancer Policy Settlement
• Hatch-Waxman Provision Splits High Court In Generics Row
• UK Plan To Share Patient Data With Drug Industry Draws Ire
• Nixon Peabody Wins Over FDA Insider From Reed Smith
• Roche Scoops Up Verum Diagnostica
• Sanofi Presses Fed. Circ. To Nix Dr. Reddy's Allegra Win
• A Sign Of Future Biosimilars Litigation?
• High Court To Tackle Novo Nordisk's Generic Drug Fight
• Judge Refuses To Lift Ban On Generic Lovenox
• Pfizer Can't Shake Birth Defect Suit Over Worker's Child
• Mayo Case Could Clarify Patentability, Expand On Bilski
• Davis & Gilbert Botched Dance Film Copyright: $8M Suit
• Stent Wars: Return Of The Lost Patent
• Hagens Berman Off Hook In Ala. Firm's Atty Fee Battle
• Spectralytics Adds To $22M IP Verdict Against Cordis
• House Bill Would Open Door To Private FCPA Suits
• The Murky Waters Of Off-Label Liability
• Fed. Circ. Keeps Teva Out Of Luck Over Crestor Patent
• Walgreen, Kroger Join Fray Over Wyeth's Effexor Tactics
• Carlyle Unit Adds French Medical Casting Biz
• Bausch & Lomb Snaps Up Argentinian Contacts Co.